Volume 4, Number 2—June 1998
Synopsis
Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome
Table 2
Illness | O serotype | No. of strains studied | No. (%) with
>1 log killa, |
Median log kill (interquartile range) |
||
---|---|---|---|---|---|---|
Pool 1c | Pool 2c | Pool 1 | Pool 2 | |||
GBSd | 19 | 7 | 1 (14) | 0 (0) | 0.53 (0.18-0.63) | 0.39 (0.08-0.52) |
Enteritis | 19 | 11 | 0 (0) | 0 (0) | 0.37 (0.09-0.47) | 0.48 (0.29-0.50) |
GBS | non-19 | 10 | 3 (30) | 3 (30) | 0.70 (0.44-1.18) | 0.43 (0.03-1.32) |
Enteritis | non-19 | 16 | 8 (50) | 7 (44) | 0.90 (0.24-2.00) | 0.59 (0.35-2.53) |
All | 19 | 18 | 1 (6) | 0 (0) | 0.38 (0.17-0.58) | 0.45 (0.23-0.52) |
All | non-19 | 26 | 11 (42) | 10 (38) | 0.70 (0.26-1.86) | 0.54 (0.17-2.27) |
aBacterial suspensions were incubated in either NHS or heat inactivated NHS at 37°C for 1 hr as described in text, and net CFU (NHS minus HINHS) determined. Values greater than 1 log10 kill were considered to denote a serum-susceptible strain.
bComparison of O:19 strains with non-O:19 strains: Pool 1, odds ratio = 12.5, p = 0.008; Pool 2, odds ratio = undefined, p = 0.003.
cPool 1 consists of C. jejuni-antibody positive serum from five healthy adults; Pool 2 consists of C. jejuni-antibody negative serum from two healthy adults.
dGBS = Guillain-Barré syndrome.
Page created: December 15, 2010
Page updated: December 15, 2010
Page reviewed: December 15, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.